Uncategorized

H1N1 and Student Health Centers

As a service to our student health center clients, I want to share a few websites that provide good information on the H1N1 influenza virus relative to campus health.

The American College Health Association has a good link to the latest CDC information on H1N1: www.acha.org/info_resources/flu_H1N1_2009.cfm.

The following link takes you to a Google map that shows where cases of H1N1 have been identified: maps.google.com/maps/ms

The CDC maintains the latest information on H1N1.  Learn more at www.cdc.gov/h1n1flu/.

If you want to extend your research further, please take a look at the Consortium for North American Higher Education Collaboration.

PCA Pharmaceuticals enables medication dispensing in health clinics by providing prepackaged pharmaceuticals and a medication tracking system. 

Schedule a free claims analysis now.

Let’s Talk now

Leader in AI-driven health benefits navigation Healthee partners with Northwind

Katherine Lurk | Mar 28th, 2025
A game-changer for employers looking to cut costs and gain control With healthcare costs continuing to rise, employers are seeking new ways to rein in spending without sacrificing the quality of benefits. This partnership enables Healthee clients to optimize prescription drug management, reducing costs through preferable generic drug pricing, high-touch chronic care programs, and more. … more »

continue reading

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading